BioChem Pharma Inc. (NASDAQ:BCHXF) of Laval, Quebec,announced Wednesday that its investigational new drug (IND)application on lamivudine for treating hepatitis B has beenapproved by the FDA.

The company said that it plans early Phase II dosing trials inCanada and Europe as well. Glaxo Group Ltd. is responsible forfunding and conducting the clinical development andregistration of lamivudine.

(c) 1997 American Health Consultants. All rights reserved.